Reviewer’s report

Title: Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: A retrospective survey

Version: 2 Date: 8 February 2012

Reviewer: Lina Eliasson

Reviewer’s report:

I am satisfied with the changes and explanations provided by the authors. I particularly commend the authors for the graphic representations of the data prompted by the other reviewer’s comments.

Minor essential revisions:

The paper need another final proof reading by a native English speaker as there are still some instances of incorrect/unsuitable use of language and grammar.

For example:

1. last sentence on page 8 should be "correcting FOR interactions between..."

2. The sentence "Imatinib prescription was actually stopped..." in 3rd paragraph page 10 needs rephrasing. It is unclear if the treatment was stopped on the advice of a clinician or not, and if these re-started treatment. It is also unclear if the 15 stopped because of side effects as well, but only temporarily? It may also be more appropriate in this context to talk about stopping/discontinuing imatinib treatment/regimen, instead of prescription?

3. The last sentence on page 11 is very unclear - e.g. "to discriminate patient consideration to stop..." does not make sense? Also same comment as above, in this context it may be more suitable to use "stop/discontinue imatinib treatment"?

4. First sentence in second paragraph on page 13 starting "From the patient perspective..." needs clarifying. I also struggle to find the details of these results in the result section? In the result section on the patient perspective this is not mentioned.

Level of interest: An article of importance in its field

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I have received honoraria from Novartis and Bristol-Myers Squibb. I have no other competing interest to declare.